Kurt joined Abingworth in January 2015, and brings over 30 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies Iambic, Jasper, Orbus, SFJ Pharmaceuticals and Tizona Therapeutics. In addition, he is on the board of CymaBay.
Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics. He is based in Menlo Park.
